Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis

Kirill Gorshkov,* Kimihiro Susumu, Jiji Chen, Miao Xu, Manisha Pradhan, Wei Zhu, Xin Hu, Joyce C. Breger, Mason Wolak, and Eunkeu Oh*

ABSTRACT: The first step of SARS-CoV-2 infection is binding of the spike protein’s receptor binding domain to the host cell’s ACE2 receptor on the plasma membrane. Here, we have generated a versatile imaging probe using recombinant Spike receptor binding domain conjugated to fluorescent quantum dots (QDs). This probe is capable of engaging in energy transfer quenching with ACE2-conjugated gold nanoparticles to enable monitoring of the binding event in solution. Neutralizing antibodies and recombinant human ACE2 blocked quenching, demonstrating a specific binding interaction. In cells transfected with ACE2-GFP, we observed immediate binding of the probe on the cell surface followed by endocytosis. Neutralizing antibodies and ACE2-Fc fully prevented binding and endocytosis with low nanomolar potency. Importantly, we will be able to use this QD nanoparticle probe to identify and validate inhibitors of the SARS-CoV-2 Spike and ACE2 receptor binding in human cells. This work enables facile, rapid, and high-throughput cell-based screening of inhibitors for coronavirus Spike-mediated cell recognition and entry.

KEYWORDS: quantum dot, SARS-CoV-2, spike, receptor binding domain, angiotensin converting enzyme 2, fluorescence, endocytosis

The severe acute respiratory syndrome coronavirus of 2019 (SARS-CoV-2) is known to cause the coronavirus disease of 2019 (COVID-19).1 The global SARS-CoV-2 viral pandemic has resulted in millions of COVID-19 cases around the world. As of August 27, 2020, there have been over 24 million cases globally with over 828 000 confirmed deaths.2 This deadly virus has prompted a global mobilization of research activity. Because much of the biology and pathogenesis of COVID-19 is unknown, and there are few therapeutic options available to patients, the field of drug discovery and development for COVID-19 antivirals requires tools and reagents to study the viral mechanisms of infection in order to identify targets for therapeutic intervention.

The first step of SARS-CoV-2 infection involves the binding of the highly glycosylated Spike’s S1 subunit receptor binding domain (RBD) to the host cell’s angiotensin converting enzyme 2 (ACE2), a transmembrane enzyme expressed on the plasma membrane surface.3,4 Because the Spike and its binding to the ACE2 receptor play such a vital role in initiating viral infection, the development of probes to study this interaction is needed by virtually all researchers engaged in SARS-CoV-2 drug discovery efforts.5

An ideal tool would be able to (1) monitor Spike/ACE2 binding, (2) measure the cellular spatiotemporal dynamics of Spike/ACE2 binding and internalization, and (3) scale for high-throughput drug screening. To this end, we have developed versatile nanoparticle probes consisting of Spike subunits conjugated to quantum dots (QDs). Although considerably smaller than an average SARS-CoV-2 virion,6 these QD probes may approximate the virus particle shape and mimic its interactions with human cells. As such, they can be considered as model "pseudovirions" that facilitate the study of Spike protein–protein interactions and spatiotemporal dynamics.

The ideal QD includes features such as well-tailored emission characteristics and the ability to serve as a central anchor for multiple spike proteins. QDs have garnered significant attention over conventional organic fluorophores due to their unique photophysical properties that include (1) size- and composition-
dependent tuning of fluorescence spectra, (2) broad excitation spectra, (3) high molar absorptivity, (4) high fluorescence quantum yield (QY), and (5) photochemical stability.\(^6\)–\(^9\) Because QDs are photostable and relatively small in size and their surfaces can be easily functionalized with a series of biological molecules, there is great interest in developing QD-based Förster resonance energy transfer (FRET) biosensing systems with various energy transfer partners.\(^10\) One of the best energy acceptors for QDs is gold nanoparticles (AuNPs), due to their large absorptivity in the visible electromagnetic spectrum.\(^11\)–\(^15\)

In this work, we have combined the utility of fluorescent QDs, AuNPs, and ACE2-green fluorescent protein tagged (ACE2-GFP) cells to allow for facile monitoring of Spike-ACE2 interactions. Hereafter, we refer to the conjugates of Spike subunits bound to a central QD as "QD-[subunit]" (e.g., QD-RBD) and ACE2 receptors bound to a central AuNP as "AuNP-ACE2". We designed an energy transfer system to monitor Spike-ACE2 binding \textit{in vitro} where QD fluorescence is quenched by the nearby AuNP upon binding. This quenching can be disrupted by unlabeled ACE2 or neutralizing SARS-CoV-2 antibodies competing with or blocking QD-Spike binding to ACE2-AuNP, respectively. We further applied QD-RBD to...
ACE2-GFP to directly image Spike-ACE2 endocytosis [endo-(RBD:ACE2)] using real-time confocal microscopy and high-resolution single-molecule tracking in living cells.

Our research supports the idea that endocytosis of Spike bound to ACE2 is one potential mechanism for viral entry. These assays can identify SARS-CoV-2 antivirals and suggest that QD-RBD conjugates can be used for high-throughput screening (HTS) as well as nanoparticle-based diagnostics for the detection of viral particles.17,18

### RESULTS AND DISCUSSION

**Biochemical Assays. Nanoparticle-Based Assay Design.**

We initially focused on developing an energy transfer system to monitor the interaction between Spike and ACE2, using QD-RBD (green QD514 fluorescence maximum at 514 nm) (Figure 1d) and AuNP-ACE2 that quenches QD fluorescence with close proximity facilitated by RBD-ACE2 binding. Photoluminescence (PL) quenching of QDs is dependent on the binding affinity, conjugation ratio, and the integral overlap of donor–acceptor pairs (details in Methods). For cellular assays, QD-RBD and ACE2-GFP internalization was monitored using

| Table 1. Characteristics of Nanoparticles and Nanoparticle–Protein Conjugates |
|---|
| **emission peak** | **extinction coefficient (M$^2$ cm$^{-1}$)** | **TEM size (nm)** | **hydrodynamic size (intensity mode, nm)** | **hydrodynamic size (number mode, nm)** |
| QD$_{608}$-CL4 | 608 nm (FWHM $\sim$ 26 nm) (QY $\sim$ 30%) | $10.0 \pm 0.93$ | $16.6 \pm 0.6$ | $12.2 \pm 0.1$ |
| QD$_{608}$-RBD | $10.1 \pm 0.89$ | $23.8 \pm 2.4$ | $19.9 \pm 0.9$ |
| QD$_{608}$-S1 | $1.2 \times 10^1$ @592 | $28.2 \pm 1.1$ | $23.4 \pm 0.7$ |
| QD$_{608}$-S1+52 | $56.1 \pm 0.9$ | $53.1 \pm 1.6$ |
| QD$_{514}$-CL4 | 514 nm (FWHM $\sim$ 34 nm) (QY $\sim$ 40%) | $8.4 \pm 0.84$ | $13.2 \pm 0.5$ | $10.8 \pm 1.6$ |
| QD$_{514}$-RBD | $8.2 \pm 0.72$ | $21.8 \pm 2.3$ | $17.0 \pm 1.3$ |
| AuNP-NTA | $5.6 \pm 0.7$ | $15.6 \pm 0.5$ | $11.8 \pm 0.4$ |
| AuNP-ACE2 | $1.4 \times 10^1$ @520 | $21.7 \pm 0.7$ | $17.4 \pm 1.7$ |

aData shown as mean $\pm$ SD.
orange-emitting QDs (QD608, fluorescence maximum at 608 nm) (Figure 1c) and GFP signal (fluorescence maximum at 509 nm). Using the pseudovirion QD-RBD, we studied RBD:ACE2 internalization and its inhibition by recombinant ACE2 with the fragment crystallizable (Fc) region of the human immunoglobulin IgG1 (ACE2-Fc) or neutralizing antibodies. For this, QD surfaces were modified with compact ligands (CL4) and AuNPs with dihydrolipoic acid (DHLA) mixed with nitrilotriacetic acid-modified DHLA (DHLA-PEG-NTA, DHLA-NTA)19 (Figure 1a). QDs have narrow emission spectra, and measurements using transmission electron microscopy (TEM) determined their diameter to be 10.4 nm for orange QD608 and 8.4 nm for green QD514 (Figure 1b). TEM also confirmed that the QD sizes and shapes were not affected by ligand exchange nor protein conjugation and that the QDs were well dispersed (Table 1 and Supplementary Figure 1). AuNP exhibited a surface resonance peak at 520 nm, and the size was 5.6 nm as measured by TEM (Figure 1b, Supplementary Figure 1). The hydrodynamic sizes of NPs in an aqueous solution were 13.2 and 16.6 nm for QD514-CL4 and QD608-CL4, respectively, and 15.6 nm for AuNP-NTA, which were larger than the TEM core sizes due to the hydration layer and ligand layer20 (Table 1). Next, histidine-tagged RBD (RBD-His) and histidine-tagged ACE2 (ACE2-His) were conjugated to NPs via coordination directly to the QD surface or NTA on the AuNP surface (details in Methods). After conjugation, the QD hydrodynamic size was increased by 7 nm with RBD (molar ratio of RBD/QD = 8, hereafter), 15 nm with S1 (S1/QD = 4), and 40 nm with S1 + S2 (S1 + S2/QD = 3), which were reasonable increases according to the protein sizes (Table 1).

Figure 3. NP-based inhibition assay. (a) Left: The structure of neutralizing antibody (top) bound to SARS-CoV-2 Spike RBD (bottom, green). Right: Schematic diagram of the inhibition assay depicting blocking of the interaction between RBD and ACE2 and the resulting inhibition of energy transfer from QD to AuNP. (b) PL recovery of QD514-RBD in the presence of neutralizing antibody Ab1. (c) Inhibition test using anti-Spike antibody without neutralizing ability, showing almost no PL recovery of QD514-RBD. (d) Calculated EC50s for neutralizing antibodies Ab1 and Ab2 were 60 nM and 125 nM with R2 > 99%, respectively.

The hydrodynamic size of AuNP was increased by 6 nm with ACE2 conjugation (ACE2/AuNP = 3). Gel electrophoresis revealed decreases in the mobility shifts as the conjugation ratio of RBD to QD increased from 0 to 16 and confirmed efficient conjugation of RBD-His to QD as well as ACE2-His to AuNP (Supplementary Figure 1).
which was longer than that for general organic dye acceptors (typically $R_0 < 10$ nm), owing to the large extinction coefficient of AuNP ($\varepsilon = 1.4 \times 10^7$ M$^{-1}$ cm$^{-1}$ at 520 nm).\(^{24}\) With QD514-AuNP, the FRET model provided the best fit to our experimental data with the specifically calculated and estimated distances, which was different from our previous study using QDs and ultrasmall AuNPs (1.5 nm) and other literature reports.\(^{15,23}\) Here, the calculated FRET model estimated higher efficiency than other models because the extinction coefficient of 5 nm AuNPs is 2−3 orders of magnitude higher than that of 1.5 nm AuNPs. The NVET model moderately estimated the experimental data, while the NSET model fit poorly because it does not account for acceptor size. While we observed consistent QD quenching using 3 nm AuNP-ACE2 and QD514-RBD, the FRET model underestimated the efficiency of smaller AuNPs due to the larger $R$-dependence (Methods, Supplementary Figure 2). $Q_{D_{514}}$S1 was also tested as the energy donor and exhibited much lower efficiency because the larger size of S1 compared to RBD (76.5 kDa vs 26.5 kDa) resulted in increased separation, $R$ (Supplementary Figure 3).

The TEM images of the QD-RBD: AuNP-ACE2 complex captured clustering of QD and AuNP (Figure 2c, Supplementary Figure 2), and the decreased distance between NPs further corroborated specific RBD-ACE2 binding, while control samples without protein conjugates did not show any clustering. However, we could not completely exclude the inner-screening effect of AuNPs, the electron transfer, or the electrostatic interaction as additional contributions to quenching.\(^{23,24}\)

Regardless of the fit to the models, the observed PL quenching indicated the binding between the Spike subunit and ACE2, demonstrating that QD-Spike is a viable method for the production of pseudovirions that can be monitored in real time by their emission characteristics.

**Biologics Inhibit NP-Based Energy Transfer.** After confirming that QD514-RBD quenching could be used to monitor RBD-ACE2 binding, we devised a method to test the inhibitory activity of biological molecules (Figure 3a). As a proof-of-concept, Fc-tagged recombinant ACE2 (ACE2-Fc) was used in a competition assay to block the interaction of QD514-RBD and AuNP-ACE2. Addition of 0.9 μM free ACE2-Fc resulted in 90% PL recovery and a half-maximal effective concentration (EC$_{50}$) of 200 nM (Supplementary Figure 3). We then tested the efficacy of neutralizing antibodies Ab1 and Ab2, specific for SARS-CoV-2 S1 or RBD, respectively, and found that the PL of QD514-RBD was fully recovered in the presence of the neutralizing antibodies (Figure 3b and Supplementary Figure 3). As a control, we tested another non-neutralizing anti-spike antibody and observed no PL recovery (Figure 3c). The calculated EC$_{50}$ using normalized PL was 60 nM and 125 nM with $R^2 > 99\%$ for Ab1 and Ab2, respectively (Figure 3d). These results indicate that our pseudovirions can enable facile and rapid biochemical screening for repurposed or newly synthesized drugs in addition to neutralizing antibodies or other biologics to prevent SARS-CoV-2 infection.

**Cell-Based Assays.** Quantum Dot Conjugates Induce ACE2-Spike Translocation. The biochemical assays described
Figure 5. QD<sub>608</sub>-RBD-induced translocation of ACE2-GFP is blocked using endocytosis inhibitor Dyngo-4a. (a) Representative image montage of ACE2-GFP signal (yellow) in HEK293T clone 2 treated with 10 nM QD<sub>608</sub>-RBD. ACE2-GFP is represented by a yellow look-up table. (b) Same cells from (a) showing the QD<sub>608</sub>-RBD signal (magenta). Control cells were incubated with Optimem I alone. Dyngo-4a-treated cells were first preincubated with compound for 15 min. Time course spans 3 h and imaging began immediately after treating cells with QD<sub>608</sub>-RBD. Images were captured using a 63× objective. Scale bar, 25 μm. (c) High-content analysis averages of spot count for ACE2-GFP and QD<sub>608</sub>-RBD. Curves were fit using nonlinear regression. N ≥ 1100 cells from 4 fields each from 10 wells per condition, representative of three experiments. Error bars indicate SD. (d) Single-particle imaging of QD (left) and overlay with tracks (right) in ACE2-GFP HEK293T cells. Scale bar, 5 μm. (e) The ensemble mean of all mean square displacements (MSD) (1562 tracks) is shown as a black solid line. The grayed area represents the weighted standard deviation over all MSD curves. (f) Distribution of one-step jump distances with fitted curve (red solid line) of QDs in the ACE2-GFP HEK293T cells.
above demonstrated how QDs conjugated to SARS-CoV-2 Spike can act as a pseudovirion and bind to ACE2. To understand whether these nanoparticle probes were active in a cell-based system, we stably transfected a C-terminal GFP-tagged ACE2 fusion protein into HEK293T cells (ACE2-GFP HEK293T”). This line propagated well, had a high transfection efficiency, and expressed high levels of ACE2 on the plasma membrane. ACE2-GFP clone 2 was treated with 100 nM QD_{514}-RBD or QD_{608}-RBD for 3 h, and the live cells were imaged using an Opera Phenix automated high-content confocal microscope (Figure 4).

The control unconjugated QDs did not enter cells, nor did they induce any changes in the localization of ACE2-GFP (Figure 4a). QD_{514}-RBD and QD_{608}-RBD were both observed to internalize into cells and induced strong translocation of ACE2-GFP. Importantly, the separate ACE2-GFP and QD_{608}-RBD signals were strongly colocalized, with little to no QD_{608} signal independent of ACE2-GFP fluorescence. The QD_{514} signal could not be discerned from the ACE2-GFP signal because of overlapping emission spectra and bleed-through as seen in stably transfected ACE2-Exp23F3 cells that do not have a GFP tag on ACE2 (Supplementary Figure 4); therefore it was selected for subsequent cell-based experiments. Furthermore, the QD-RBD fluorescence was only observed in ACE2-GFP cells as seen with ACE2-GFP HEK293T clone 1 that had a lower transfection efficiency. High-content analysis of fluorescent signals demonstrated a large assay window between cells treated with QD_{608}-RBD and cells treated with unconjugated QD_{608} when analyzing spot counts, indicative of internalized QDs and ACE2 receptor (Figure 4b). We also generated QD_{528} during initial optimizations conjugated to the virtually full length recombinant SARS-CoV-2 S1+S2 ECD-His protein. QD_{528}-S1+S2 bound to the cell surface, and subsequently intracellular puncta could be observed, although internalization was reduced compared to that observed with QD-RBD (Supplementary Figure 4). In addition, recombinant SARS-CoV-2 RBD alone was able to induce ACE2-GFP translocation (Supplementary Figure 5). Furthermore, QDs conjugated to the original SARS Spike, SARS-CoV S1, were internalized and strongly colocализed with ACE2-GFP (Supplementary Figure 5).

To verify that ACE2-GFP cells indeed expressed ACE2, fixed cells were immunostained with mouse anti-ACE2 antibody, and no independent yellow or magenta signal corresponding to GFP and QD, respectively, was observed (Figure 4c). Similarly, no uptake of QD_{608}-RBD was observed in wild-type (WT) HEK293T cells (Figure 4d). In contrast to untagged ACE2-Exp239F3, WT HEK239T did not express detectable levels of ACE2 as assessed by immunofluorescence staining (Figure 4e).

**QD_{608}-RBD Enters Cells and Induces ACE2-GFP Internalization through Endocytosis.** We confirmed that QD_{608}-RBD could be used at concentrations as low as 5 nM and still observe binding, internalization, and translocation of ACE2-GFP (Supplementary Figure 6). Concentrations of 10 and 20 nM were used in subsequent experiments to ensure sufficient amounts of QD-RBD. One potential mechanism of this translocation and internalization of ACE2-GFP bound to QD_{608}-RBD is dynamin- and clathrin-dependent receptor endocytosis, a mechanism that has been proposed for viral entry in some cell types. To confirm this hypothesis, we conducted live-cell imaging of ACE2-GFP clone 2 cells treated with OptiMem I as a control, 10 or 20 nM QD_{608}-RBD, and 20 μM Dyngo-4a, a dynamin inhibitor (Figure 5a, Supplementary Videos 1–6).

Signals from ACE2-GFP and QD_{608}-RBD were captured for cells treated with and without QD_{608}-RBD or Dyngo-4a. QD_{608}-RBD rapidly bound to ACE2-GFP cells and began internalizing with ACE2-GFP within 10 min to form endo(RBD-ACE2). Dyngo-4a alone did not affect the ACE2-GFP localization (Supplementary Video 4), but treatment with Dyngo-4a prior to QD_{608}-RBD treatment robustly blocked endo(RBD-ACE2) (Supplementary Videos 5,6). The inhibitory effect of Dyngo-4a was more apparent when quantifying the signal for QD_{608}-RBD than for ACE2-GFP. The residual signal from the clustering of ACE2-GFP at the membrane was identified as “spots” during the high-content analysis (Figure 5b). However, QD_{608}-RBD, while able to bind at the cell surface, was not able to enter cells in the presence of Dyngo-4a, and therefore the quantification revealed a strong inhibitory effect (Figure 5c).

**Single-Molecule Tracking Confirms Endocytosis of QD_{608}-RBD.** To further study the spatiotemporal dynamics of QD_{608}-RBD, we utilized inclined/total internal reflection fluorescence (TIRF) illumination microscopy, a high-resolution single-molecule microscopy method to measure the kinetics of individual quantum dots binding and internalizing into the ACE2-GFP HEK293T cell line (Figure 5d–f, Supplementary Video 7). In order to image single QDs, a very low concentration of QD_{608}-RBD (200 pM) was incubated with ACE2-GFP HEK293T cells for 20 min to capture bound and endocytosing particles. We observed very fast binding (within minutes) of QD_{608}-RBD to the surface of ACE2-GFP HEK293T cells. Furthermore, the fluorescence intensity fluctuation of QD_{608}-RBD on the plasma membrane under TIRF mode was observed, suggesting single QD blinking (Supplementary Video 7). The localization of single QDs was determined through two-dimensional Gaussian fitting. The average mean square displacement (MSD) curve clearly indicated the nature of confined motion of QDs (Figure 5e). The ensemble MSD analysis revealed the average behavior of QD_{608}-RBD. In order to better understand the mobility behavior in the population, we calculated the jump distance traveled by each QD track from one frame to the next and found three different mobilities of QD_{608}-RBD in ACE2-GFP HEK293T cells: immobile (0.03 μm^2/μs), slow (0.13 μm^2/μs), and fast (0.84 μm^2/μs), occupying 32%, 52%, and 16% of the population, respectively (Figure 5f). Most of the tracks corresponded to immobile and slow population, demonstrating QD_{608}-RBD interactions with the ACE2 receptor. The fast diffusion coefficient population likely reflects receptor-mediated endocytosis, as evidenced by active transport that was observed during imaging. Our results for the slow diffusion of QD_{608}-RBD corresponded to those shown in the literature with regard to membrane compartments where confined diffusion was determined to be 0.12 μm^2/μs. These results indicate that the nanoparticle movement was vastly different from free diffusion and suggest that QD_{608}-RBD interacted with the ACE2 receptor. While this experiment was conducted after 20 min of QD_{608}-RBD incubation, longer-term incubations may reveal different endo(RBD-ACE2) mobility dynamics based on the endosomal location in the cell.

**Inhibition of Spike Using Antibodies and Recombinant ACE2.** The development of neutralizing antibodies and biologics as SARS-CoV-2 antivirals has garnered much attention because they can directly block viral entry. Using QD_{608}-RBD, we demonstrated that neutralizing antibodies developed against SARS-CoV-2 S1 and RBD potently blocked the binding
and internalization phenotype observed in ACE2-GFP HEK293T cells (Figure 6 and Supplementary Figure 7). While Ab1 was raised against SARS-CoV-2 S1-Fc, Ab2 was raised against SARS-CoV-2 RBD. However, our data showed Ab1 was more potent than Ab2 against RBD (Figure 6a,b). This result is consistent with the biochemical inhibitions carried out prior to the cell-based assays and ELISA assay data reported by the vendor. As with the biochemical inhibition assays, ACE2-Fc was less effective at blocking QD-RBD binding than were the antibodies; Ab1 was 8-fold more potent than ACE2-Fc (Figure 6c–e).

Figure 6. Neutralizing antibodies and ACE2-Fc block QD608-RBD-induced endocytosis. (a) Representative image montage of ACE2-GFP (yellow) HEK293T clone 2 treated with 10 nM QD608-RBD (magenta). Digital phase contrast (cyan) was used during live-cell imaging to identify cell bodies. Cells were treated with neutralizing antibodies Ab1 and Ab2 starting at 100 nM. (b) High-content analysis averages for ACE2-GFP and QD608-RBD spot count treated with neutralizing antibodies. (c) Representative image montage of ACE2-GFP (yellow) HEK293T clone 2 treated with 10 nM QD608-RBD (magenta). Digital phase contrast (cyan) was used during live-cell imaging to identify cell bodies. Cells were treated with ACE2-Fc starting at 1.5 μM. (d) High-content analysis averages for ACE2-GFP and QD608-RBD spot count treated with ACE2-Fc. N ≥ 2000 cells from triplicate wells each from three independent experiments. Error bars indicate SD. (e) Table showing the EC50 values for Ab1, Ab2, and ACE2-Fc based on spot count from (b) and (d). Images were captured using a 40× objective. (f) Illustration of QD608-RBD internalization via receptor-mediated endocytosis and the inhibition using Ab1, Ab2, and ACE2-Fc.
The addition of any exogenous material, whether small molecule or biologic, may have cytotoxic effects that can confound any observed experimental phenomenon. In order to assess the cytotoxicity of \( \text{QD}_{608}\)-RBD, we conducted ATPlite cell viability assays following the biologics inhibition assays. The ATPlite luminescence signal is dependent upon the amount of adenosine triphosphate (ATP) in cells. Cells with low viability will have lower levels of ATP than cells with high viability. Neither \( \text{QD}_{608}\)-RBD, Ab1, Ab2, nor ACE2-Fc exhibited any cytotoxicity after 3 h of treatment (Supplementary Figure 8). The negative control cells treated with \( \text{QD}_{608}\)-RBD alone and the positive control cells treated with Optimem I alone both had equal levels of ATP as reported by the ATPlite luminescence-based reading. These data support the idea that QDs used in this study were not cytotoxic, as previously reported,33 nor was the RBD domain from SARS-CoV-2 itself.

**Epithelial Lung Cancer Cell Line Calu-3 Can Uptake \( \text{QD}_{608}\)-RBD.** The permissiveness of different cell types and tissues for SARS-CoV-2 infection is a central question for the research community.34–36 It is important to understand how and whether cells are infected by SARS-CoV-2 and what those effects may be, cytopathic or otherwise. To shed some light on this question and to explore the utility of the QD-RBD reagent further, we cultured Calu-3 cells,38 a cancer cell line derived from lung epithelium and commonly used in coronavirus infection assays, and treated them with 20 nM \( \text{QD}_{608}\)-RBD. A maximum intensity projection from a 28 μm confocal Z-stack demonstrated entry into some Calu-3 cells, particularly ones that were isolated as opposed to clustered (Supplementary Figure 9). We further immunostained Calu-3 cells for ACE2 expression using the mouse anti-ACE2 antibody and found some level of recognition by the ACE2 receptor, and blocking the down-stream effects such as membrane fusion1 and viral endocytosis.25,37,39 The stably transfected ACE2-GFP cell line has been used as an effective platform to study SARS-CoV-2 entry.40 Altogether, we have effectively established a platform technology not only for this SARS-CoV-2 viral pandemic but also for other viruses that have a Spike-mediated cell recognition and entry step as the first step in viral infection.43 We further postulate that the QD-Spike conjugates may act as highly specific and potent delivery vehicles for drugs and other molecules of therapeutic interest.

**METHODS**

**Reagents and Materials.** CdO (99%) and tri-n-octylphosphine (TOP; min. 97%) were purchased from Strem Chemicals. Behenic acid (99%), 1,2-hexadecanediol (technical grade, 90%), oleylamine (technical grade, 70%), n-octanethiol (98.5+%), and LiOH (≥98%) were purchased from Sigma-Aldrich. I-Octadecene (ODE; technical grade, 90%) was purchased from Acros Organics. Selenium dioxide (≥97%) was purchased from Fluka. Oleic acid (technical grade, 90%) and 2-(2-aminoethoxy)ethanol (98%) were purchased from Alfa Aesar. All other chemicals, including solvents, were purchased from Sigma-Aldrich or Acros Organics and were used as received.

Dulbecco’s modified essential media (DMEM) (10313021), tetrachloroauric(III) acid, sodium hydroxide, ascorbic acid, sodium citrate, boric acid, Optimem I (11058021), penicillin/streptomycin (15140037), goat-anti-mouse AlexaFluor 488 (A32723; RRIDI-DAB: 2632725), High Content Screening Cell Mask Deep Red (H33750), Hoechst 33342 (H3570), and Lipofectamine 2000 (L3000001) were purchased from ThermoFisher Scientific. Mouse anti-ACE2 antibody (E-11): sc-390851 was purchased from Santa Cruz. Hefclone fetal bovine serum (FBS) (SH30071-03) was purchased from General Electric Healthcare. Paraformaldehyde (15714S, 35%) was purchased from Electron Microscopy Sciences. Greiner 96-well poly-d-lysine-coated clear-bottom black microplates (655946) were purchased from Greiner Bio-One. SARS-CoV S1-His (40150-V08B1), SARS-CoV-2 S1S2 ECD-His (40589-V08B1), SARS-CoV-2 S1-His (40591-V08H), SARS-CoV-2 RBD-His (40592-V08B1), anti-SARS-CoV-2 S1 neutralizing antibody mouse mAb Ab1 (40591-MM43), and anti-SARS-CoV-2 RBD neutralizing antibody mouse mAb Ab2 (40592-MM57) were purchased from Sino Biological. ACE2-Fc (Z03484) was purchased from Genesiscript. pCMV6-AC-ACE2-GFP (RG208442) plasmid was purchased from Origene Technologies. Dyngro-4a (ab12068) was purchased from Abcam. ACE2-Fc-HEK293T (CB-97100-203) and ACE2-untagged Exp293F cells were purchased from Codex Biosolutions.

**QD Synthesis.** The 514 nm emitting ZnSe/CdSe/ZnS core–shell QDs and 528 nm emitting CdSe/CdS/ZnS core–shell QDs were synthesized as previously described.44,45 The 608 nm emitting CdSe/CdS/ZnS core–shell QDs were synthesized via modification of published procedures. (i) The CdSe core was synthesized following published procedures with some modifications.46 CdO (77 mg, 0.60 mmol), behenic acid (0.613 g, 1.80 mmol), and ODE (5.0 mL) were loaded in a 50 mL three-neck flask. The mixture was heated to 260 °C under N2 to dissolve the Cd precursor. The mixture was cooled to 50 °C and the reaction mixture was degassed at 100 °C for 30 min. Then, the reaction mixture was cooled below 50 °C, oleic acid (0.60 mL) was added dropwise, the heating mantle was removed, and the reaction mixture was cooled to 240 °C at a rate of ∼25 °C/min under N2. In 3 min after the temperature reached 240 °C, oleic acid (0.60 mL) was added dropwise, the heating mantle was removed, and the reaction mixture was cooled below 50 °C. TOP (0.6 mL), oleylamine (0.6 mL), hexane (9 mL), and methanol (18 mL) were added to the reaction mixture, and the methanol layer was discarded after vigorous stirring for a few minutes. An identical washing procedure was repeated a few more times. The QD solution was transferred to a 40 mL vial, and excess isopropanol and ethanol were added to flocculate the QDs. The mixture was centrifuged at 3800 rpm for 5 min. The supernatant was discarded, and the QD pellet was dissolved in CHCl3. The final CdSe QD concentration was estimated following the literature method.47 (ii) Precursors for 0.2 M Cd oleate, 0.2 M Zn...
oleate, and 0.2 M n-octanethiol solutions for the overcoating procedure, calculated based on the target size of AuNPs and seed size, was added to the growth solution followed by addition of L-ascorbic acid (2 mM final concentration). The reaction mixture was stirred for 30 min at room temperature and kept without stirring for an additional 24 h for the complete reaction. Reaction completion was confirmed by the red shift of the Au band peak and the corresponding decrease of the ascorbic acid and azure peaks in the near-UV region (<300 nm) using UV–vis absorption spectroscopy. The final sizes were confirmed by TEM measurement.

**Ligand Exchange of AuNPs with DHLA-NTA/DHLA-PG-NTA Ligands.** Synthesis of the nitritolactric acid-modified thioctic acid (TA-NTA/TA-PG-NTA, disulfide ring in closed form; DHLA-NTA/ DHLA-PG-NTA, ring in open form) was as previously described. For ligand exchange, the presynthesized larger AuNPs were added to an excess ligand mixture. Briefly, 10 mL of as-synthesized citrate-modified AuNPs was mixed with an excess amount of mixed ligand stock solution containing 50% DHLA, 45% DHLA-NTA, and 5% DHLA-PG-NTA, which had been deprotected from the ester derivative with an equivalent molar concentration of NaOH for 1 h. The solution was stirred for 8 h and adjusted to pH 8 by adding NaOH, and the dispersion was purified from free ligands by three cycles of centrifugation using a membrane filtration device (Amicon). For Ni coordination for NTA ligand, an excess amount of NiCl2 (500 times of 5 nm AuNP) was directly added to the as-prepared NTA-modified AuNPs and gently stirred for 30 min to promote the interaction between the Ni2+ and NTA on the AuNP surface. The Ni2+-NTA-modified AuNPs were purified using a centrifugal membrane filter (Amicon) and kept at 4 °C until further required.

**Protein Conjugation to NPs: QD-Spike and AuNP-ACE2.** Histidine-tagged RBD (RBD-His) was conjugated to the QD surface through coordination between the imidazole units of histidine and the ZnS QD shell. The ACE2-His was conjugated to the NTA on the AuNP after activation with the nickel ion that simultaneously coordinates the imidazole units of histidine and NTA. For QD-Spike conjugates, the prepared QDs were mixed with stock solution of the histidine-tagged Spike at targeted ratios of protein per QD, and the reaction mixture was adjusted to pH 8 by addition of borate solution (20 mM). After 1 h at room temperature with gentle agitation, BSA (20 μM final concentration) was added to the reaction mixture to prohibit potential nonspecific binding. The prepared QD-Spike conjugates were washed using a centrifuge membrane filter (Amicon Ultra) (100 kDa molecular cut-off, Millipore Inc.) to remove small chemicals, and the mixture was redispersed in BSA buffer and stored at 4 °C until further use.

For AuNP-ACE2 conjugates, histidine-tagged ACE2 protein was directly added to the Ni-coordinated AuNPs at targeted ratios of ACE2 per AuNP, and the mixture was kept at 4 °C for at least 8 h to complete the reaction (see Results section for AuNP/Ace ratios studied in this work). BSA (20 μM final concentration) was added to the reaction mixture to prohibit nonspecific binding. The prepared AuNP-ACE2 conjugates were washed using a centrifuge membrane filter (100 kDa molecular cut-off, Millipore Inc.) to remove low molecular weight impurities, and the mixtures were redispersed in borate buffer (with BSA) and stored at 4 °C until further use.

**Unconjugated NP Characterization.** Three different techniques were used to characterize the QDs and AuNP used in this study: (1) Electronic absorption and PL emission spectra were recorded using a Shimadzu UV-1800 UV–vis spectrophotometer and a Horiba, Inc. fluorometer (excitation at λ = 395 nm), respectively. (2) Dynamic light scattering (DLS) was used to measure hydrodynamic size. The samples were transferred into a square-shaped capillary, and measurements were recorded on a ZetaSizer Ultra instrument equipped with a HeNe laser source (λ = 633 nm) (Malvern Instruments Ltd., Worcestershire, UK) and analyzed using Dispersion Technology Software (Malvern Instruments Ltd.) as previously described. (3) Structural characterization and elemental analysis of the as-prepared NPs were carried out using a JEOL 2200-FX analytical high-resolution transmission electron microscope with a 200 kV accelerating voltage. TEM samples were prepared by spreading a drop (5–10 μL) containing the NPs onto an ultrathin carbon/holey support film on a 300 mesh Au grid (Ted Pella, Inc.).
Inc.) and letting it dry. The concentration of NPs used for TEM was 50–100 nM. Individual particle sizes were measured using a Gatan digital micrograph (Pleasanton, CA, USA); average sizes along with standard deviations were extracted from analysis of at least 50–100 nanoparticles.

**Gel Electrophoresis.** Conjugation of proteins to QD608 or AuNPs was confirmed using an electrophoretic mobility shift assay with a 1% Agarose gel and 1x TBE buffer at 90 mV. Gel images were taken every 5 min utilizing a Bio-Rad ChemiDoc XRS+ gel imager under fluorescent light for QDs or Epi-white light for AuNPs. Ratios of RBD to QD608 varied from 0 to 16, and those of ACE2 to AuNP from 1 to 3. The retardation of migration through the gel as the ratio of protein to NP increased confirmed conjugation of the protein to NPs.

**NP-Based Energy Transfer Assay.** QD-RBD conjugates (or QD-S1) were mixed with AuNP-ACE2 conjugates with targeted ratios of AuNP-ACE2 to QD-RBD ranging from 0 to 10. The reaction mixtures were incubated for 2 h at room temperature. The general concentration of QD was approximately 3 to 10 nM. A basic buffer containing 20 mM borate and 20 μM BSA was used to stabilize all reactions, unless described separately. The QD fluorescence spectra were obtained at each ratio with 395 nm excitation. The fluorescence images of a series of solutions at increasing AuNP-ACE2 to QD-RBD ratios were taken under excitation with a hand-held UV lamp at 375 nm. For inhibition assays, the desired amount of inhibitor was incubated with QD-RBD for 2 h at room temperature, followed by adding AuNP-ACE2 and incubating for 2 h at room temperature. Fluorescence spectra were obtained in an identical manner to that described above.

**Quantum Yield Measurements.** Fluorescence quantum yields (Φ) were measured at room temperature with fluorescein in 0.1 N NaOH (Φ = 0.93)50 for QD514 and QD528 or Rhodamine 101 in ethanol (Φ = 1.0)53 for QD608 as standards. The obtained fluorescence spectra were corrected using the spectral output of a calibrated light source supplied by the National Bureau of Standards. The parameters in eq 1 include the integrated PL intensities of the QD and standard in arbitrary units (a.u.), PLQD and PLstd, their optical density at excitation wavelength, ODQD and ODst, and the refractive indices of their media, nQD and nstd, respectively.50

$$\Phi_{QD} = \frac{\int PL_{QD}(\lambda) \, d\lambda}{\int PL_{std}(\lambda) \, d\lambda} \cdot \frac{OD_{QD}}{OD_{std}} \cdot \frac{n_{std}^2}{n_{QD}^2} \cdot \Phi_{std}$$

**Generation of Stably Transfected Cell Lines.** ACE2-GFP HEK293T. HEK293T cells were seeded into cells in a six-well plate with 70–80% confluency. For each well, the cells were transfected with 2.5 μg of pCMV6-AC-ACE2-GFP plasmid using Lipofectamine 3000 (ThermoFisher). Twenty-four hours later, the cells were dissociated with trypsin and transferred into 100 mm dishes. The cells were selected with 1.0 mg/mL G418 for 2–3 weeks. Single colonies were picked into 24-well plates containing 1.0 mL of DMEM with 10% FBS supplemented with 1.0 mg/mL G418. The clones with the brightest GFP signals were picked for propagation.

**ACE2-Exp293F.** Exp293F cells (ThermoFisher) were seeded into cells in a six-well plate with 70–80% confluency. For each well, the cells were transfected with 2.5 μg of pCMV-ACE2-ires-Puromycin plasmid (Codex BioSolutions) using Lipofectamine 3000. Twenty-four hours later, the cells were dissociated with trypsin and transferred into 100 mm dishes. The cells were selected with 1 μg/mL puromycin for 2–3 weeks. Single colonies were picked into 24-well plates containing 1 mL of DMEM and 10% FBS supplemented with 1 μg/mL puromycin. Western blot was performed to screen the ACE2 expression clones with an ACE2-specific antibody (sc-390851, Santa Cruz).

**Cell Culture.** ACE2-GFP and ACE2-Exp293 cells were cultured using DMEM complete with 10% FBS and 1% Pen/Strep in large T175 flasks until 80% to 90% confluence prior to seeding in 96-well plates at 25,000 cells per well. Cells were incubated overnight at 37 °C and 5% CO₂.

Calu-3 cells were cultured using EMEM complete with 10% FBS and 1% Pen/Strep in large T175 flasks until 80% to 90% confluence prior to seeding in 96-well plates at 20,000 cells per well. Cells were incubated overnight at 37 °C and 5% CO₂.

**Immunofluorescence Staining.** Cells were washed three times with PBS prior to fixation using 4% PFA in PBS with 0.1% BSA for 30 min. Cells were washed three times followed by permeabilization with 0.5% saponin in Cell Staining Buffer for 15 min followed by blocking in Cell Staining Buffer for an additional 45 min. Then, cells were incubated with 1:200 mouse anti-ACE2 antibody overnight at 4 °C. The next day, cells were washed three times with PBS and incubated with 1:1000 goat anti-mouse AlexaFluor 488 for 1 h followed by 3X PBS washes. Finally, cells were incubated with Hoechst 33342 to stain the nuclei and HCS Cell Mask Deep Red when required. Cells were washed three final times in PBS prior to sealing of the plates for imaging.

**QD and Spike Treatment.** Prior to treatment with QD-Spike conjugates, cells were washed once with prewarmed Optimem I. Stock QD or recombinant protein solution was diluted directly in Optimem I, and 50 μL of QD working solution was added to cells for the indicated amount of time at 37 °C and 5% CO₂.

**High-Content Imaging and Analysis.** Cells were placed into the Opera Phenix (PerkinElmer) automated confocal imaging system that was preheated to 37 °C. A 40X or 63X water immersion objective was used to capture multiple fields per well at a single z-position. Cells were not washed further prior to imaging. Images were captured with digital phase contrast, green and orange channels. QDs were first exposed to UV light prior to capturing emission using the orange (λ = 570–630 nm) emission bandpass. Images were uploaded into the Columbus analyzer (PerkinElmer) and analyzed using custom protocols. Where applicable, the digital phase contrast channel was used to identify the cell bodies, and the spots were identified in the green (Cam1: λ = 435–550 nm) and orange (Cam2: λ = 570–650 nm) channels for ACE2-GFP and QD608 respectively. Data were exported into Microsoft Excel, and graphs were plotted using Graphpad Prism V8.4.3. For inhibition experiments using neutralizing antibodies or ACE2-Fc, data were normalized to the Optimem I only treated cells (100%, positive control) or QD608-RBD treated cells (0%, negative control).

For Dyno-4a endocytosis inhibition experiments, cells were preincubated with 20 μM Dyno-4a in Optimem I for 15 min. Afterward, 2X concentrated solutions of Dyno-4a and QD608-RBD was added to an equal volume of Optimem I for a final concentration of 20 μM Dyno-4a and 10 or 20 nM QD608-RBD. Imaging began immediately after the addition of QD608-RBD with minimal delay. Images were captured every 10 min for 3 h. For endocytosis experiments using Dyno-4a, data were normalized to the Optimem I only treated cells (100%, positive control) or QD608-RBD treated cells (0%, negative control).

Image montages were constructed using Fiji (NIH). All images for each channel were first stacked before using the auto feature to equally adjust the brightness and contrast across the conditions. For time-lapse videos, images were registered using the StackReg plugin in Fiji, and stacks were saved as .avi files. Videos were subsequently slowed in Windows 10 video editor (Microsoft) and saved as .mpg files.

**Single-Molecule Fluorescence Microscopy.** Single-molecule imaging experiments were conducted on a custom-built Nikon Ti microscope coupled with a 100X oil-immersion objective lens (NA = 1.49), a multiband dichroic (405/488/561/633 BrightLine quadr-band pass filter, Semrock, USA), and a piezo z-stage (ASI, USA). The lasers were focused into the back pupil plane of the objective to generate wide-field illumination. A Nikon N-STORM module was used to control the angle of the laser beam for generating inclined illumination. The emission was collected by the same objective passing through a quadr-bandpass emission filter (FF01-446/523/600/677-25, Semrock, USA) in front of an sCMOS camera (Prime 95B, Teledyne Photometrics). The microscope, lasers, and the camera were controlled through NIS-Elements (Nikon, USA). A 488 nm laser was used excite the QDs.

**Single-Molecule Tracking and Analysis.** Single-molecule tracking was performed with custom-written MATLAB software.6,4 The MATLAB scripts, SLIMFAST/evalSPT, were used to localize and track single molecules. The positions of the diffraction-limited spots in the trajectories were determined with a 2D Gaussian fit. A maximal expected diffusion constant was set to connect localizations between consecutive frames.
Mean square displacements were calculated from $x,y$ positions as previously described. We determined the instantaneous diffusion coefficients from a linear fit of the initial points of the MSD (between time lag 1 and 5). The MSD curves for all the tracks were computed with @msdanalyzer script.

For jump distance analysis, the probability that a particle located at position $r$ at time $t$ in two dimension, will be found at position $r'+dr$ at time $t+\tau$ is given by:

$$p(r,t)dr = \int_0^{2\pi} r^2 \phi(r,t) d\theta = \frac{2\pi dr}{4\pi D t} \exp\left(-\frac{r^2}{4Dt}\right)$$

where $D$ is the diffusion constant.

In the case of 2D diffusion, the displacement probability was obtained through integrating the above equation over the circular shell of width $dr$:

$$p(r,t)dr = \int_0^{2\pi} r^2 \phi(r,t) d\theta = \frac{2\pi dr}{4\pi D t} \exp\left(-\frac{r^2}{4Dt}\right)$$

Experimentally, this probability distribution can be approximated by counting the jump distances within respective intervals $(r, r + dr)$ traveled by a single QD during a given time (camera exposure time).

The diffusion coefficient of different species was determined through nonlinear fitting the jump distance histogram with multicomponents. The F-test was performed to compare the single-, two-, and three-component fitting models.

**Statistical Analysis and Illustration.** For biochemical assays, all experiments were performed with at least three independent experiments, and the TEM size was analyzed with 50—100 randomly chosen nanoparticles in different images. For cell-based assays, all experiments where statistical analysis was performed included three independent experiments with three independent wells unless otherwise noted. Data shown as mean ± standard deviation (SD). Concentration—response curves and EC$_{50}$ values were generated using nonlinear regression. The illustration in Figure 6f was created using Biorender.

**ASSOCIATED CONTENT**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsnano.0c05975.

Video 1. Confocal time lapse of ACE2-GFP HEK293T treated with Optimem I in the ACE2-GFP channel (yellow) (MP4)

Video 2. Confocal time lapse of ACE2-GFP HEK293T treated with 20 nM QD608-RBD in the QD608-RBD channel (magenta) (MP4)

Video 3. Confocal time lapse of ACE2-GFP HEK293T treated with 20 nM QD608-RBD in the ACE2-GFP channel (yellow) (MP4)

Video 4. Confocal time lapse of ACE2-GFP HEK293T treated with 20 µM Dynngo-4a in the ACE2-GFP channel (yellow) (MP4)

Video 5. Confocal time lapse of ACE2-GFP HEK293T treated with 20 nM QD608-RBD and 20 µM Dynngo-4a in the QD608-RBD channel (magenta) (MP4)

Video 6. Confocal time lapse of ACE2-GFP HEK293T treated with 20 nM QD608-RBD and 20 µM Dynngo-4a in the ACE2-GFP channel (yellow) (MP4)

Video 7. Single-molecule imaging time lapse of ACE2-GFP HEK293T treated with 200 pM QD608-RBD in the QD608-RBD channel (AVI)

Supplemental discussion section describing in more detail the impetus for biochemical and cell-based assays and the rationale for choosing the methods that were used in the study; detailed description of the experiments and their implications; methods for the energy transfer models (PDF)

**AUTHOR INFORMATION**

**Corresponding Authors**

Kirill Gorschkov — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States; orcid.org/0000-0002-4652-8818; Email: kirill.gorschkov@nih.gov

Eunkeu Oh — Optical Sciences Division, Code 5600, Naval Research Laboratory, Washington, D.C. 20375, United States; orcid.org/0000-0003-1641-522X; Email: eunkeu.oh@nrl.navy.mil

**Authors**

Kimihiro Susumu — Optical Sciences Division, Code 5600, Naval Research Laboratory, Washington, D.C. 20375, United States; Jacobs Corporation, Hanover, Maryland 21076, United States

Wei Zhu — Optical Sciences Division, Code 5600, Naval Research Laboratory, Washington, D.C. 20375, United States

Shengli Qu — Optical Sciences Division, Code 5600, Naval Research Laboratory, Washington, D.C. 20375, United States

Jiji Chen — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States

Miao Xu — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States

Manisha Pradhan — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States

Wei Zhu — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States

Xin Hu — National Center for Advancing Translational Sciences, Rockville, Maryland 20850, United States

Joyce C. Breger — Center for Bio/Molecular Science and Engineering, Code 6900, Naval Research Laboratory, Washington, D.C. 20375, United States

Mason Wolak — Optical Sciences Division, Code 5600, Naval Research Laboratory, Washington, D.C. 20375, United States

**Author Contributions**

Experimental: KG, KS, MX, MP, WZ, JCB, EO. Data analysis: KG, JCB, EO. Manuscript conception: KG, MW, EO. Manuscript writing: KG, JCB, EO, EH. Critical manuscript editing and discussion: KG, KS, MW, EO.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

We acknowledge Dr. Chiu and Dr. Liou at AIMLab at the University of Maryland, College Park, for their help in operating the TEM facility. We also thank NCATS scientists Dr. Matthew Hall and Dr. Catherine Chen for discussions as well as NRL scientists Dr. Michael Stewart and Dr. Alan Huston for discussions. We thank Dr. Zeenat Asghar Shyr for critical reading of the manuscript. We also appreciate the initial suggestion from Dr. Craig Thomas at NCATS for making the connection between NRL and NCATS. This research was supported in part by the Intramural Research Program of the National Center for Advancing Translational Sciences, NIH. Naval Research Laboratory provided funding via its internal Nanoscience Institute. Reagent preparation was supported via the NRL COVID-19 base fund.
REFERENCES

(1) Rothan, H. A.; Byrareddy, S. N. The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. J. Autoimmun. 2020, 109, 102433.

(2) Dong, E.; Du, H.; Gardner, L. An Interactive Web-Based Dashboard to Track COVID-19 in Real Time. Lancet Infect. Dis. 2020, 20, 533–534.

(3) Walls, A. C.; Park, Y.-J.; Tortorici, M. A.; Wall, A.; Muccigiani, A. T.; Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020, 181, 281–292.

(4) Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W. A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus–Induced Lung Injury. Nat. Med. 2005, 11, 875–879.

(5) Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F. Network-Based Drug Repurposing for Novel Coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020, 6, 1–18.

(6) Brueche, M., Jr.; Moronne, M.; Gin, P.; Weiss, S.; Alivisatos, A. P. Semiconductor Nanocrystals as Fluorescent Biological Labels. Science 1998, 281, 2013–2016.

(7) Alivisatos, P. The Use of Nanocrystals in Biological Detection. Nat. Biotechnol. 2004, 22, 47–52.

(8) Sapsford, K. E.; Pons, T.; Medintz, I. L.; Mattoussi, H. Biosensing with Luminescent Semiconductor Quantum Dots. Sensors 2006, 6, 925–953.

(9) Algar, W. R.; Susumu, K.; Delehanty, J. B.; Medintz, I. L. Semiconductor Quantum Dots in Bioanalysis: Crossing the Valley of Death. Anal. Chem. 2011, 83, 8826–8837.

(10) Hildebrandt, N.; Spillmann, C. M.; Algar, W. R.; Pons, T.; Stewart, M. H.; Oh, E.; Susumu, K.; Diaz, S. A.; Delehanty, J. B.; Medintz, I. L. Energy Transfer with Semiconductor Quantum Dot Bioconjugates: A Versatile Platform for Biosensing. Energy Harvesting, and Other Developing Applications. Chem. Rev. 2017, 117, 536–711.

(11) Oh, E.; Hong, M.-Y.; Lee, D.; Nam-S.-H.; Yoon, H. C.; Kim, H.-S. Inhibition Assay of Biomolecules Based on Fluorescence Resonance Energy Transfer (FRET) between Quantum Dots and Gold Nanoparticles. J. Am. Chem. Soc. 2005, 127, 3270–3271.

(12) Dyadyusha, L.; Yin, H.; Jaiswal, S.; Brown, T.; Baumberg, J. J.; Betzig, E. Extended-Resolution Illumination TIRF Microscopy at High Speed with Multiple Colors. J. Visualized Exp. 2016, 53988.

(13) Bhatia, D.; Arumugam, S.; Nasilowski, M.; Joshi, H.; Wunder, C.; Chambon, V.; Prakash, V.; Grazon, C.; Nadal, B.; Maiti, P. K.; Johannes, L.; Dupertret, B.; Krishnan, Y. Quantum Dot-Loaded Monofunctionalized DNA Icosahedra for Single-Particle Tracking of Endocytic Pathways. Nat. Nanotechnol. 2016, 11, 1112–1119.

(14) Li, D.; Shao, L.; Chen, B.-C.; Zhang, X.; Zhang, M.; Mose, B.; Millie, D. E.; Beach, J. R.; Hammer, J. A.; Pasham, M.; Kirchhausen, T.; Baird, M. A.; Davidson, M. W.; Xu, P.; Betzig, E. Extended-Resolution Structured Illumination Imaging of Endocytic and Cytoskeletal Dynamics. Science 2015, 349, Aab3500.

(15) Jiang, S.; Hillyer, C.; Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020, 41, 335–359.

(16) Wang, C.; Li, W.; Drabek, D.; Okba, N. M.; Van Haperen, R.; Osterhaus, A. D.; Van Kuppeveld, F. J.; Haagmans, B. L.; Grosveld, F.; Bosch, B.-J. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat. Commun. 2020, 11, 1–6.

(17) Lu, D.; Zhang, Q.; Ge, J.; Wang, R.; Sun, J.; Xiangyang, G.; Jiazheng, Y.; Shao, B.; Zou, B.; Song, S.; Yang, X.; Yu, J.; Lan, J.; Yuan, J.; Wang, H.; Zhao; J.; Zhang; Wang; Shi, X.; Liu, E.; et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020, 584, 115–119.

(18) Maksooudian, C.; Soenen, S. J.; Susumu, K.; Oh, E.; Medintz, I. L.; Manshan, B. A. Multivariate Evaluation of Quantum Dot Size and Surface-Grrafted Peptide Density on Cellular Uptake and Cytotoxicity. Bioconjugate Chem. 2020, 31, 1077–1087.

(19) Letko, M.; Marzi, A.; Munster, V. Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses. Nat. Microbiol. 2020, 5, 562–569.

(20) Chen, L.; Li, X.; Chen, M.; Feng, Y.; Xiong, C. The ACE2 Expression in Human Emphasizes New Important Mechanism of Heart Injury among Patients Infected with SARS-CoV-2. Cardiovasc. Res. 2020, 116, 1097–1101.
(38) Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N.-H.; Nitsche, A. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020, 181, 271–280.

(39) Yang, N.; Shen, H.-M. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *Int. J. Biol. Sci.* 2020, 16, 1724–1731.

(40) Yan, S.; Sun, H.; Bu, X.; Wan, G. New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection. *Front. Pharmacol.* 2020, 11, 912.

(41) Monteil, V.; Kwon, H.; Prado, P.; Hagelkrüys, A.; Wimmer, R. A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Del Pozo, C. H.; Prosper, F. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell* 2020, 181, 905–913.

(42) Glebov, O. O. Understanding SARS-CoV-2 Endocytosis for COVID-19 Drug Repurposing. *FEBS J.* 2020, 1–8.

(43) Gallagher, T. M.; Buchmeier, M. J. Coronavirus Spike Proteins in Viral Entry and Pathogenesis. *Virology* 2001, 279, 371–374.

(44) Susumu, K.; Field, L. D.; Oh, E.; Hunt, M.; Delehanty, J. B.; Palomo, V.; Dawson, P. E.; Huston, A. L.; Medintz, I. L. Purple-, Blue-, and Green-Emitting Multishell Alloyed Quantum Dots: Synthesis, Characterization, and Application for Ratiometric Extracellular pH Sensing. *Chem. Mater.* 2017, 29, 7330–7344.

(45) Susumu, K.; Oh, E.; Delehanty, J. B.; Pinaud, F.; Gemmill, K. B.; Walper, S.; Breger, J.; Schroeder, M. J.; Stewart, M. H.; Jain, V. A New Family of Pyridine-Appended Multidentate Polymers as Hydrophilic Surface Ligands for Preparing Stable Biocompatible Quantum Dots. *Chem. Mater.* 2014, 26, 3327–3344.

(46) Chen, O.; Chen, X.; Yang, Y.; Lynch, J.; Wu, H.; Zhuang, J.; Cao, Y. C. Synthesis of Metal–Selenide Nanocrystals Using Selenium Dioxide as the Selenium Precursor. *Angew. Chem., Int. Ed.* 2008, 47, 8638–8641.

(47) Jasieniak, J.; Smith, L.; Van Embden, J.; Mulvaney, P.; Califano, M. Re-Examination of the Size-Dependent Absorption Properties of CdSe Quantum Dots. *J. Phys. Chem. C* 2009, 113, 19468–19474.

(48) Chen, D.; Zhao, F.; Qi, H.; Rutherford, M.; Peng, X. Bright and Stable Purple/Blue Emitting CdS/ZnS Core/Shell Nanocrystals Grown by Thermal Cycling Using a Single-Source Precursor. *Chem. Mater.* 2010, 22, 1437–1444.

(49) Susumu, K.; Oh, E.; Delehanty, J. B.; Blanco-Canosa, J. B.; Johnson, B. J.; Jain, V.; Hervey IV, W. J.; Algar, W. R.; Boeneman, K.; Dawson, P. E. Multifunctional Compact Zwitterionic Ligands for Preparing Robust Biocompatible Semiconductor Quantum Dots and Gold Nanoparticles. *J. Am. Chem. Soc.* 2011, 133, 9480–9496.

(50) Lakowicz, J. R. 2.10 Quantum Yield Standards, Principles of Fluorescence Spectroscopy, 2nd ed.; Springer Science & Business Media: New York, 2013; pp 52–53.

(51) Dwyer, C. L.; Díaz, S. N. A.; Walper, S. A.; Samanta, A.; Susumu, K.; Oh, E.; Buckhout-White, S.; Medintz, I. L. Chemoenzymatic Sensitization of DNA Photonic Wires Mediated through Quantum Dot Energy Transfer Relays. *Chem. Mater.* 2015, 27, 6490–6494.

(52) Magde, D.; Wong, R.; Seybold, P. G. Fluorescence Quantum Yields and Their Relation to Lifetimes of Rhodamine 6G and Fluorescein in Nine Solvents: Improved Absolute Standards for Quantum Yields. *Photochem. Photobiol.* 2002, 75, 327–334.

(53) Karstens, T.; Kobs, K. Rhodamine B and Rhodamine 101 as Reference Substances for Fluorescence Quantum Yield Measurements. *J. Phys. Chem.* 1980, 84, 1871–1872.

(54) Chen, J.; Zhang, Z.; Li, L.; Chen, B.-C.; Revyakin, A.; Hajj, B.; Legant, W.; Dahan, M.; Lionnet, T.; Betzig, E.; Tjian, R.; Liu, Z. Single-Molecule Dynamics of Enhancerome Assembly in Embryonic Stem Cells. *Cell* 2014, 156, 1274–1285.

(55) Saxton, M. J.; Jacobson, K. Single-Particle Tracking: Applications to Membrane Dynamics. *Annu. Rev. Biophys. Biomol. Struct.* 1997, 26, 373–99.

(56) Tarantino, N.; Tinevez, J. Y.; Crowell, E. F.; Boisson, B.; Henriques, R.; Mhlanga, M.; Agou, F.; Israël, A.; Laplantine, E. TNF and IL-1 Exhibit Distinct Ubiquitin Requirements for Inducing NEMO-IKK Supramolecular Structures. *J. Cell Biol.* 2014, 204, 231–45.

(57) Maza, D.; Abernathy, A.; Golob, N.; Morisaki, T.; McNally, J. G. A Benchmark for Chromatin Binding Measurements in Live Cells. *Nucleic Acids Res.* 2012, 40, No. E119.